// App-Quantinova.ai

1196 : Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN

Researchers

Presenter

  • Gwenda F. Ligon

Principal Investigators

  • Jay S. Lillquist

  • Scott B. Seibel

  • Jerry Wallweber

  • Veronique Neumeister

  • David L. Rimm

  • Theresa M. LaVallee

  • Diego Alvarado

Medical Centers

  • Kolltan Pharmaceuticals, New Haven, CT

  • Monogram Biosciences, Inc., South San Francisco, CA

  • Yale University, New Haven, CT

Locations

  • United States

Companies

  • Kolltan Pharmaceutic

  • Monogram Biosciences

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

Biomarkers

  • Amphiregulin

Drug/Treatment

  • amphiregulin

  • Erbitux

  • KTN3379

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved